A lab test and algorithms for identifying clients at risk for treatment failure

…, DW Smart, K Shimokawa, SW Sutton - Journal of clinical …, 2005 - Wiley Online Library
Many branches of medicine rely heavily on lab tests to monitor client treatment response
and use this information to modify their treatment. By contrast, those who offer psychological …

[PDF][PDF] Measurement of microbial cells by optical density

S Sutton - Journal of Validation technology, 2011 - microbiologynetwork.com
… Please send your comments and suggestions to column coordinator Scott Sutton at scott.
sutton@microbiol.org or journal coordinating editor Susan Haigney at shaigney@advanstar.…

[PDF][PDF] Accuracy of plate counts

S Sutton - Journal of validation technology, 2011 - microbiologynetwork.com
… Please send your comments and suggestions to column coordinator Scott Sutton at scott.
sutton@microbiol.org or journal managing editor Susan Haigney at shaigney@advanstar.com. …

[PDF][PDF] Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor

…, YA He, S Ninkovic, D Behenna, KT Tran, S Sutton… - Cancer cell, 2021 - cell.com
The CDK4/6 inhibitor, palbociclib (PAL), significantly improves progression-free survival in
HR + /HER2 − breast cancer when combined with anti-hormonals. We sought to discover PAL …

[PDF][PDF] The most probable number method and its uses in enumeration, qualification, and validation

S Sutton - Journal of Validation Technology, 2010 - microbiologynetwork.com
… er comments, questions, and suggestions are to help us fulfill our objective for this colease
send your comments and suggestions mn coorddina nator Scott Sutton at scott.sutton@ ol.org …

[HTML][HTML] Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance

…, YA He, W Diehl, N Grable, PP Kung, S Sutton… - Nature …, 2016 - nature.com
Polycomb repressive complex 2 (PRC2) mediates gene silencing through chromatin
reorganization by methylation of histone H3 lysine 27 (H3K27). Overexpression of the complex and …

Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer

…, MA Ornelas, J Solowiej, SC Sutton… - Journal of Medicinal …, 2021 - ACS Publications
Control of the cell cycle through selective pharmacological inhibition of CDK4/6 has proven
beneficial in the treatment of breast cancer. Extending this level of control to additional cell …

Optimization of orally bioavailable enhancer of zeste homolog 2 (EZH2) inhibitors using ligand and property-based design strategies: identification of development …

…, S Sharma, J Sherrill, J Spangler, AE Stewart, S Sutton… - 2018 - ACS Publications
A new series of lactam-derived EZH2 inhibitors was designed via ligand-based and
physicochemical-property-based strategies to address metabolic stability and thermodynamic …

Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one …

…, H Shen, T Smeal, J Solowiej, S Sutton… - Journal of Medicinal …, 2016 - ACS Publications
First generation EGFR TKIs (gefitinib, erlotinib) provide significant clinical benefit for NSCLC
cancer patients with oncogenic EGFR mutations. Ultimately, these patients’ disease …

Determination of inoculum for microbiological testing

S Sutton - Journal of GXP compliance, 2011 - search.proquest.com
… to column coordinator Scott Sutton at scott.sutton@microbiol.… Sutton also operates the
PMFList email discussion group and … He may be reached by e-mail at scott.sutton@microbiol.org. …